Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3873862 · 1 trial · 1 indication
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3873862 (Part A) | EXPERIMENTAL | LY3873862 administered orally as single dose. |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered orally. |
| LY3873862 (Part B) | EXPERIMENTAL | LY3873862 administered orally as multiple doses. |
| Placebo (Part B) | PLACEBO_COMPARATOR | Placebo administered orally. |
| LY3873862 (Part C) | EXPERIMENTAL | LY3873862 administered orally as multiple doses. |
| Placebo (Part C) | PLACEBO_COMPARATOR | Placebo administered orally. |
| Name | Type | Description |
|---|---|---|
| LY3873862 | DRUG | Administered orally. |
| Placebo | DRUG | Administered orally. |
Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation * Body mass index (BMI) within the range 18.0 to 32.0 kilograms per meter squared (kg/m²) * Are male or female participants, including those of childbearing potential Exclusion Criteria: * Have a histor...
LY3873862 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development, studied in healthy participants. The drug is not approved and remains under investigation.
LY3873862 is being studied in healthy participants as part of early clinical development. Its intended therapeutic use has not been established, as it is still in Phase 1 trials.
LY3873862 is developed by Eli Lilly and Company, a biopharmaceutical company traded on the NYSE under the ticker LLY.
LY3873862 is in Phase 1 clinical development. A Phase 1 study in healthy participants has been completed, and the drug remains investigational.
LY3873862 has one completed Phase 1 trial, NCT05492201, titled "A Study of LY3873862 in Healthy Participants." The trial enrolled 84 healthy participants in the United Kingdom and was placebo-controlled and double-blind.
LY3873862 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development, with a completed study in healthy participants.